BRISBANE, Calif., Sept. 21 /PRNewswire-FirstCall/ -- WHAT: VaxGen, Inc. Matthew J. Pfeffer, VaxGen's CFO and Senior Vice President, Finance and Administration, will present a company summary at the UBS Global Life Sciences Conference. The presentation will be available to the public through a webcast. (Photo: http://www.newscom.com/cgi-bin/prnh/19991112/VAXGENLOGO ) WHERE/WHEN: The Grand Hyatt, New York, NY 4:00 p.m. EDT, Wednesday, September 27, 2006 HOW: To listen and view the webcast presentation, go to Webcasts in the Investor Relations section of VaxGen's web site at www.vaxgen.com/invest and click on UBS Global Life Sciences Conference. About VaxGen
VaxGen, Inc. is a biopharmaceutical company engaged in the development, manufacture and commercialization of biologic products for the prevention and treatment of human infectious diseases, including anthrax and smallpox. The company has been awarded an $877.5 million U.S. government contract to provide 75 million doses of its recombinant anthrax vaccine for civilian biodefense. Based in Brisbane, Calif., VaxGen operates a wholly owned manufacturing facility in California and is a shareholder in Celltrion, Inc., a South Korean joint venture established to provide contract manufacturing to the global pharmaceutical industry. For more information, please visit the company's web site at: http://www.vaxgen.com .
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/19991112/VAXGENLOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk photodesk@prnewswire.comVaxGen, Inc.CONTACT: Cynthia Kelly, +1-650-624-1041, for VaxGen, Inc.
Web site: http://www.vaxgen.com//
